上交所：中际旭创(03308.HK)调入沪港通下港股通标的名单，自下一港股通交易日起生效。

The FDA has approved Revolution Medicines' pancreatic cancer drug Daraxonrasib, which will be marketed as Rasonque. The drug is the first therapy targeting one of the disease's key molecular pathogenic mechanisms. A late-stage trial published in May showed Daraxonrasib nearly doubled typical survival in an aggressive form of pancreatic cancer to 13.2 months versus 6.7 months with chemotherapy, the current standard of care.

路透调查：标普500指数预计将在2026年结束时达到7,900点（5月份调查为7,620点）。道琼斯工业平均指数预计将在2026年结束时达到54,500点（5月份调查为52,500点）。